Peptides: What Works, What’s Hyped, and What to Watch For

The word “peptide” has gone from biochemistry textbook to wellness magazine cover in just a few years. Patients ask me about BPC-157 for joint pain, semaglutide for weight, epitalon for longevity, and half a dozen others, often in the same visit. The honest answer is that the peptide world contains three very different categories, and treating them as one is the most common mistake I see. A small group of FDA-approved peptide drugs has produced some of the most impressive cardiometabolic data in modern medicine. A larger group of compounded peptides sits in regulatory limbo with thin clinical evidence. And a third category, research chemicals sold online, comes with documented contamination and dosing problems. Knowing which is which is the difference between a sound medical decision and an expensive experiment on yourself.

What peptides actually are

Peptides are short chains of amino acids, the same building blocks that make up every protein in your body. Insulin is a peptide. So is the hormone that tells your brain you are full after dinner. Your body uses thousands of these molecules as messengers, carrying instructions between organs, immune cells, and tissues. With age, that signaling slows. The pituitary releases growth hormone in smaller pulses; the gut sends weaker satiety signals; mitochondria struggle to communicate their energy needs; and chronic inflammation drowns out the rest. The appeal of peptide therapy is restoring those conversations rather than overriding them with synthetic hormones. The framework is reasonable. Whether any particular peptide actually delivers on it depends entirely on which molecule, with what evidence, sourced through what supply chain.

The peptides with real evidence behind them

Three peptide drugs have transformed cardiometabolic medicine over the last several years. Semaglutide, sold as Ozempic and Wegovy, mimics the gut hormone GLP-1. The STEP 1 trial showed a mean body weight loss of 14.9% at 68 weeks, compared with 2.4% with placebo [1]. The SELECT trial, in 17,604 adults with cardiovascular disease and obesity but no diabetes, demonstrated a 20% relative reduction in death from cardiovascular causes, heart attack, or stroke [2]. The FLOW trial added a 24% reduction in kidney disease progression in type 2 diabetics with chronic kidney disease [3].

Tirzepatide, marketed as Mounjaro and Zepbound, hits both GLP-1 and GIP receptors and outperformed semaglutide head-to-head, achieving 20.2% versus 13.7% weight loss at 72 weeks in SURMOUNT-5 [4]. It also resolved liver inflammation in 44-62% of patients with metabolic-associated steatohepatitis at 52 weeks [5] and became the first FDA-approved medication for obstructive sleep apnea in adults with obesity.

A third drug, retatrutide, hits three receptors at once (GLP-1, GIP, and glucagon) and showed an 81 to 82% reduction in liver fat at 24 weeks in phase 2 [6]. It is not yet FDA-approved; phase 3 trials are ongoing.

For visceral fat specifically, tesamorelin (Egrifta) is FDA-approved with 15 to 20% reductions over 6 to 12 months, but only in HIV-associated lipodystrophy [7]. All other uses, including the popular framing of tesamorelin as a longevity peptide, are off-label.

The longevity and repair peptides where the evidence is thinner

The peptides most heavily marketed for healthy aging, joint repair, and brain function sit on much shakier ground. BPC-157, the so-called Wolverine peptide, has produced striking results in rats and mice but has never completed a single phase 3 human trial. Its proposed mechanism includes activating the same VEGFR2 angiogenic pathway that tumors hijack to grow a new blood supply [8].

GHK-Cu, the copper peptide credited with influencing more than 4,000 genes, derives that figure from a single in vitro transcriptomic screen rather than from clinical outcomes [9]. Most rigorous human evidence supports topical cosmetic use; injectable systemic GHK-Cu has no published randomized trials.

Dihexa is genuinely fascinating in cell culture, where it has been shown to trigger new synapse formation at picomolar concentrations [10]. The often-quoted phrase “10 million times more potent than BDNF” refers to that in vitro comparison, not human cognition. There are no human trials. Dihexa also activates the HGF/c-MET pathway, which is implicated in lung, gastric, hepatocellular, and several other cancers.

The notable exception in this group is thymosin alpha 1, approved in more than 35 countries (as Zadaxin) for hepatitis B and C and as immune support in cancer care, with a substantial human trial base. It works through immune modulation rather than growth signaling, a meaningfully different risk profile.

Epitalon, DSIP, semax, and selank, mostly developed in Russia, have intriguing animal data but minimal independent human evidence.

What the 2023 FDA shake-up means for you

In September 2023, the FDA placed roughly 19 peptides on Category 2 of its 503A bulk substances list, citing immunogenicity concerns, impurity profiles, and absence of human safety data. The list included BPC-157, CJC-1295, ipamorelin, semax, selank, thymosin alpha 1, TB-500, epitalon, KPV, MOTS-c, and DSIP, among others. Category 2 placement effectively cut off legitimate compounding-pharmacy supply for these substances.

In April 2026, the FDA reversed itself on 12 peptides because the original nominators had withdrawn their submissions. Seven peptides returned to formal review at the Pharmacy Compounding Advisory Committee meetings on July 23 and 24, 2026, with five more by February 2027. Removal from Category 2 does not mean approval. It returns these peptides to a gray zone pending formal rulemaking.

This matters for one practical reason. The peptide vials sold by online research-chemical suppliers without a prescription are not the same product a licensed compounding pharmacy makes under USP standards. Independent testing of online-purchased peptides has found vials containing 43 to 89% of the labeled dose, bacterial endotoxin contamination, and, in some cases, no active peptide at all [11]. The FBI issued a public service warning in February 2025 about fraudulent compounded weight-loss drugs.

The side effects worth knowing about

GLP-1 drugs cause nausea, diarrhea, or vomiting in roughly 70% of users at therapeutic doses, gallbladder disease at modestly elevated rates, and rare cases of pancreatitis. About 25-40% of the weight lost on these drugs is lean muscle mass, which becomes a serious problem after 50 unless paired with resistance training and adequate protein intake. A 2024 paper reported a small but real signal of non-arteritic ischemic optic neuropathy, a rare cause of vision loss, associated with semaglutide use [12]. The European Medicines Agency reviewed concerns about suicidal thoughts in 2024 and found no causal link.

Growth hormone-releasing peptides such as sermorelin, CJC-1295, and ipamorelin elevate IGF-1, which, in epidemiologic studies, has been associated with a higher risk of prostate, premenopausal breast, and colorectal cancer [13]. They can also cause carpal tunnel symptoms, joint pain, fluid retention, and worsened insulin sensitivity. Out-of-pocket costs for compounded peptides typically range from $200 to $600 per month, with no insurance coverage for off-label use.

A note for cancer survivors

This is the area where I am most cautious. Peptides that drive growth, proliferation, or the formation of new blood vessels raise legitimate theoretical concerns in active or recent cancer. BPC-157 and TB-500 activate VEGF-mediated angiogenesis, the same pathway tumors use to recruit blood supply. All growth-hormone-releasing peptides raise IGF-1, the most-studied mitogen in cancer epidemiology. Dihexa activates HGF/c-MET, an oncogenic pathway in numerous cancers. Tesamorelin’s own FDA label requires that any pre-existing malignancy be inactive before use.

GLP-1 drugs are a notable exception. A 1.65 million-patient analysis found that GLP-1 use was associated with a reduced incidence of 10 of 13 obesity-related cancers compared with insulin [14]. Thymosin alpha 1, used as an oncology adjunct in the countries where it is approved, also has a different risk profile. Coordinate any peptide decision with your oncologist.

Where this leaves you

The right peptide for the right person at the right time, prescribed and monitored by a knowledgeable physician, is a different proposition entirely from a vial purchased online and self-injected. The peptide field rewards those who can hold three ideas at once. Some of these molecules are extraordinarily effective. Most are unproven. The supply chain matters as much as the molecule. Use this article to ask sharper questions of your physician, not as a substitute for that conversation.

References

Peptides: What Works, What’s Hyped, and What to Watch For

Dr. Daniel Thomas, DO, MS